Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNTbm-38 in Solid Tumors and Relapsed/Refractory Peripheral T-Cell Lymphoma
NCT07842445Phase 1Not yet recruiting
- Sponsor
- GNT Biotech & Medicals
- Start
- Dec 2026
- Primary completion
- Feb 2029
01
Overview
Phase 1, open-label, single-arm trial of GNTBM-38 in solid tumor and peripheral T-cell lymphoma (PTCL), sponsored by GNT Biotech & Medicals. Primary endpoints: Maximum Tolerated Dose and Dose-Limiting Toxicities at 4 weeks, Safety and Tolerability at 4 weeks and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
GNTBM-38
03
Conditions
solid tumorperipheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07842445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07842445.